FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Donald Brophy

Research Profile

Disorders

Chemicals & Drugs

Physiology

Blood Coagulation

Concepts & Ideas

Prospective Studies

Procedures

Phenomena

Thrombin Time

Anatomy

Blood Platelets

Co-author Network

Publications

TOP 3
Gretchen M Brophy; Christina L Candeloro; Jaime R Robles; Donald F Brophy
Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
Donald F Brophy; Daniel E Carl; Spencer E Harpe; Gretchen M Brophy
An Epidemiological Study of Anemia and Renal Dysfunction in Patients Admitted to ICUs across the United States.
Avani D Joshi; Darcy Mays; Donald F Brophy; Spencer E Harpe; David A Holdford; Todd W B Gehr
Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Donald Brophy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gretchen M Brophy; Christina L Candeloro; Jaime R Robles; Donald F Brophy
Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
The Annals of pharmacotherapy 2013;47(4):447-54.
2012: Donald F Brophy; Daniel E Carl; Spencer E Harpe; Gretchen M Brophy
An Epidemiological Study of Anemia and Renal Dysfunction in Patients Admitted to ICUs across the United States.
Anemia 2012;2012():938140.
2012: Avani D Joshi; Darcy Mays; Donald F Brophy; Spencer E Harpe; David A Holdford; Todd W B Gehr
Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study.
Anemia 2012;2012():248430.
2011: Nathan J White; Donald F Brophy; Erika J Martin; Kevin R Ward
Examining platelet-fibrin interactions during traumatic shock in a swine model using platelet contractile force and clot elastic modulus.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2011;22(5):379-87.
2010: Gretchen M Brophy; Marcia L Brackbill; Katherine L Bidwell; Donald F Brophy
Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Neurocritical care 2010;13(2):176-81.
2010: Nathan J White; Erika J Martin; Yongyun Shin; Donald F Brophy; Robert F Diegelmann; Kevin R Ward
Systemic central venous oxygen saturation is associated with clot strength during traumatic hemorrhagic shock: A preclinical observational model.
Scandinavian journal of trauma, resuscitation and emergency medicine 2010;18():64.
2010: Donald F Brophy; Gregory Daniel; Matthew Gitlin; Tracy J Mayne
Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
The Annals of pharmacotherapy 2010;44(1):43-9.
2010: Nathan J White; Erika J Martin; Donald F Brophy; Kevin R Ward
Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitation.
Resuscitation 2010;81(1):111-6.
2009: Brian L Henry; Jay N Thakkar; Erika J Martin; Donald F Brophy; Umesh R Desai
Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2009;20(1):27-34.
2009: Donald F Brophy; Bonny L Bukaveckas; Andrea Ferreira-Gonzalez; Kellie J Archer; Erika J Martin; Todd W B Gehr
A pilot study of genetic polymorphisms and hemodialysis vascular access thrombosis.
Hemodialysis international. International Symposium on Home Hemodialysis 2009;13(1):19-26.
2008: Donald F Brophy
Efficacy and safety of fondaparinux and enoxaparin for acute coronary syndromes in CKD.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2008;51(5):719-23.
2007: Donald F Brophy; Erika J Martin; M E Nolte; Jan G Kuhn; Marcus E Carr
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Haemophilia : the official journal of the World Federation of Hemophilia 2007;13(5):533-41.
2007: Lena Maynor; Donald F Brophy
Risk of infection with intravenous iron therapy.
The Annals of pharmacotherapy 2007;41(9):1476-80.
2007: Donald F Brophy; Domenic A Sica
Use of enoxaparin in patients with chronic kidney disease: safety considerations.
Drug safety : an international journal of medical toxicology and drug experience 2007;30(11):991-4.
2007: Donald F Brophy; Erika J Martin; Sheryl L Carr; Barry Kirschbaum; Marcus E Carr
The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.
Thrombosis research 2007;119(6):723-9.
2006: Brian R Overholser; Donald F Brophy; Kevin M Sowinski
Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease.
Therapeutic drug monitoring 2006;28(6):807-12.
2006: Donald F Brophy; Marcus E Carr; Erika J Martin; Jürgen Venitz; Todd W B Gehr
The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
Journal of clinical pharmacology 2006;46(8):887-94.
2006: Donald F Brophy; Erika J Martin; Todd W B Gehr; Al M Best; K Paul; Marcus E Carr
Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.
Journal of thrombosis and haemostasis : JTH 2006;4(2):372-6.
2005: Donald F Brophy; Elizabeth Bd Ripley; Denise R Kockler; Seina Lee; Lori A Proeschel
Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
The Annals of pharmacotherapy 2005;39(11):1808-11.
2005: Donald F Brophy; John A Dougherty; James C Garrelts; Roy C Parish; Michael P Rivey; Janice L Stumpf; Charles T Taylor; A Scott Mathis
Venous thromboembolism prevention in acutely ill nonsurgical patients.
The Annals of pharmacotherapy 2005;39(7-8):1318-24.
2004: Donald F Brophy; Erika J Martin; Al M Best; Todd W B Gehr; Marcus E Carr
Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
Journal of thrombosis and haemostasis : JTH 2004;2(8):1299-304.
2004: Donald F Brophy; Erika J Martin; Todd W B Gehr; Marcus E Carr
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2004;44(2):270-7.
2003: Donald F Brophy; Elizabeth Bd Ripley; David A Holdford
Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.
Expert opinion on pharmacotherapy 2003;4(9):1461-9.
2002: Donald F Brophy
Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
The Annals of pharmacotherapy 2002;36(9):1466-70.
2001: Donald F Brophy; LD Wazny; Todd W B Gehr; T J Comstock; Jürgen Venitz
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
Pharmacotherapy 2001;21(2):169-74.
2000: Donald F Brophy; J F Wallace; Daniel T Kennedy; Todd W B Gehr; David A Holdford
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
Pharmacotherapy 2000;20(8):950-7.
2000: A A Pedro; Todd W B Gehr; Donald F Brophy; Domenic A Sica
The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.
Journal of clinical pharmacology 2000;40(4):389-95.
2000: LD Wazny; Donald F Brophy
Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.
The Annals of pharmacotherapy 2000;34(1):94-7.
1999: Donald F Brophy; Kevin M Sowinski; Michael A Kraus; Sharon M Moe; J E Klaunig; Bruce Mueller
Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 1999;19(6):534-9.
1999: Donald F Brophy; Michael A Crouch; DM Ruffin; LD Wazny; J M McKenney
Pharmacotherapy of dyslipidemia in postmenopausal women: weighing the evidence.
Journal of women's health & gender-based medicine 1999;8(7):901-17.
1998: Donald F Brophy; S L Ford; Michael A Crouch
Warfarin resistance in a patient with short bowel syndrome.
Pharmacotherapy 1998;18(3):646-9.
1998: Michael A Crouch; Donald F Brophy
Nonsteroidal antiinflammatory drug-induced hepatitis.
The Annals of pharmacotherapy 1998;32(3):386.
1997: Donald F Brophy; Bruce Mueller
Automated peritoneal dialysis: new implications for pharmacists.
The Annals of pharmacotherapy 1997;31(6):756-64.